Cassutt Kelly J, Orsini Michael J, Abousleiman Mojgan, Colone Dean, Tang Weimin
Hamamatsu Corp, Bridgewater, NJ, USA.
J Biomol Screen. 2007 Mar;12(2):285-7. doi: 10.1177/1087057106298538. Epub 2007 Feb 8.
The authors used a homogeneous calcium dye kit with a cell line transfected using a recombinant protein construct to screen a 50,000 compound library for G-protein coupled receptor (GPCR) agonists. Only 1 of the 365 primary hits activated Gq-coupled GPCRs, as shown using IP-ONE HTRF. Furthermore, an agonist screen against the entire compound library and same heterologous cell line using AequoScreen technology generated no false positives and identified the same positive hit. Next, a multiplex assay composed of both Fluo-3 and Fura-2-loaded cells identified 1 false positive and the same true-positive hit out of the 365 primary hits. Finally, rescreening the 365 primary hits against the parental cell line loaded using the homogeneous calcium dye kit confirmed the specificity of the same true-positive hit only. In summary, the results suggest that AequoScreen technology, IP-ONE HTRF, and multiplex assays are unique, orthogonal technologies to identify nonspecific hits.
作者使用了一种均质钙染料试剂盒和一个用重组蛋白构建体转染的细胞系,以筛选一个包含50000种化合物的文库,寻找G蛋白偶联受体(GPCR)激动剂。如使用IP-ONE HTRF所示,在365个初步筛选出的活性化合物中,只有1个激活了与Gq偶联的GPCR。此外,使用AequoScreen技术针对整个化合物文库和相同的异源细胞系进行激动剂筛选,未产生假阳性结果,并鉴定出了相同的阳性活性化合物。接下来,一项由同时装载Fluo-3和Fura-2的细胞组成的多重分析在365个初步筛选出的活性化合物中鉴定出1例假阳性结果和相同的真阳性活性化合物。最后,使用均质钙染料试剂盒对装载了365个初步筛选出的活性化合物的亲本细胞系进行重新筛选,仅证实了相同真阳性活性化合物的特异性。总之,结果表明,AequoScreen技术、IP-ONE HTRF和多重分析是用于鉴定非特异性活性化合物的独特、正交技术。